Income Tax Expense (Benefit) of Y-mAbs Therapeutics, Inc. from 31 Dec 2019 to 30 Jun 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Summary
Y-mAbs Therapeutics, Inc. quarterly and annual Income Tax Expense (Benefit) in USD history and change rate from 31 Dec 2019 to 30 Jun 2025.
  • Y-mAbs Therapeutics, Inc. Income Tax Expense (Benefit) for the quarter ending 30 Jun 2025 was $7,000, a 93% decline year-over-year.
  • Y-mAbs Therapeutics, Inc. Income Tax Expense (Benefit) for the twelve months ending 30 Jun 2025 was $394,000, a 161% decline year-over-year.
  • Y-mAbs Therapeutics, Inc. annual Income Tax Expense (Benefit) for 2024 was $146,000, a 126% decline from 2023.
  • Y-mAbs Therapeutics, Inc. annual Income Tax Expense (Benefit) for 2023 was $561,000.
  • Y-mAbs Therapeutics, Inc. annual Income Tax Expense (Benefit) for 2022 was $0.
Source SEC data
View on sec.gov
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), YoY Quarterly Change (%)
Income Tax Expense (Benefit), Annual (USD)
Income Tax Expense (Benefit), YoY Annual Change (%)

Y-mAbs Therapeutics, Inc. Quarterly Income Tax Expense (Benefit) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q2 2025 $394,000 $7,000 -$93,000 -93% 01 Apr 2025 30 Jun 2025 10-Q 08 Aug 2025 2025 Q2
Q1 2025 $301,000 $5,000 -$155,000 -97% 01 Jan 2025 31 Mar 2025 10-Q 13 May 2025 2025 Q1
Q4 2024 $146,000 $752,000 -$947,000 -486% 01 Oct 2024 31 Dec 2024 10-K 04 Mar 2025 2024 FY
Q3 2024 $801,000 $346,000 +$159,000 +85% 01 Jul 2024 30 Sep 2024 10-Q 08 Nov 2024 2024 Q3
Q2 2024 $642,000 $100,000 -$79,000 -44% 01 Apr 2024 30 Jun 2024 10-Q 08 Aug 2025 2025 Q2
Q1 2024 $721,000 $160,000 +$160,000 01 Jan 2024 31 Mar 2024 10-Q 13 May 2025 2025 Q1
Q4 2023 $561,000 $195,000 +$195,000 01 Oct 2023 31 Dec 2023 10-K 04 Mar 2025 2024 FY
Q3 2023 $366,000 $187,000 +$187,000 01 Jul 2023 30 Sep 2023 10-Q 08 Nov 2024 2024 Q3
Q2 2023 $179,000 $179,000 +$179,000 01 Apr 2023 30 Jun 2023 10-Q 12 Aug 2024 2024 Q2
Q1 2023 $0 $0 $0 01 Jan 2023 31 Mar 2023 10-Q 08 May 2023 2023 Q1
Q4 2022 $0 $0 $0 01 Oct 2022 31 Dec 2022 10-K 29 Feb 2024 2023 FY
Q3 2022 $0 $0 $0 01 Jul 2022 30 Sep 2022 10-Q 07 Nov 2022 2022 Q3
Q2 2022 $0 $0 $0 01 Apr 2022 30 Jun 2022 10-Q 08 Aug 2022 2021 Q3
Q1 2022 $0 $0 $0 01 Jan 2022 31 Mar 2022 10-Q 08 May 2023 2023 Q1
Q4 2021 $0 $0 01 Oct 2021 31 Dec 2021 10-K 30 Mar 2023 2022 FY
Q3 2021 $0 01 Jul 2021 30 Sep 2021 10-Q 07 Nov 2022 2022 Q3
Q2 2021 $0 01 Apr 2021 30 Jun 2021 10-Q 08 Aug 2022 2021 Q3
Q1 2021 $0 01 Jan 2021 31 Mar 2021 10-Q 09 May 2022 2022 Q1

Y-mAbs Therapeutics, Inc. Annual Income Tax Expense (Benefit) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $146,000 -$707,000 -126% 01 Jan 2024 31 Dec 2024 10-K 04 Mar 2025 2024 FY
2023 $561,000 +$561,000 01 Jan 2023 31 Dec 2023 10-K 04 Mar 2025 2024 FY
2022 $0 $0 01 Jan 2022 31 Dec 2022 10-K 29 Feb 2024 2023 FY
2021 $0 $0 01 Jan 2021 31 Dec 2021 10-K 30 Mar 2023 2022 FY
2020 $0 $0 01 Jan 2020 31 Dec 2020 10-K 01 Mar 2022 2021 FY
2019 $0 01 Jan 2019 31 Dec 2019 10-K 01 Mar 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.